12:00 AM
Jul 09, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

rFVIIIFc: Phase III started

Biogen Idec began the open-label, international Phase III Kids A-LONG trial to evaluate IV rFVIIIFc in about 50 male patients ages <12 with severe hemophilia A and a history of at least 50 exposure days with any marketed Factor...

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >